2-(3,3-diphenylpropyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine
![2-(3,3-diphenylpropyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine Structure](https://image.chemsrc.com/caspic/032/55011-89-7.png)
2-(3,3-diphenylpropyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine structure
|
Common Name | 2-(3,3-diphenylpropyl)-1,3,4,6,7,8,9,9a-octahydropyrido[1,2-a]pyrazine | ||
|---|---|---|---|---|
| CAS Number | 55011-89-7 | Molecular Weight | 334.49800 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C23H30N2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
| Symbol |
GHS06 |
Signal Word | Danger | |
|
Clinical pharmacokinetics of ketobemidone. Its bioavailability after rectal administration.
Eur. J. Clin. Pharmacol. 19(3) , 217-23, (1981) The pharmacokinetic constants and rectal bioavailability of the narcotic analgesic ketobemidone were determined in six male patients after surgery. Plasma concentrations were measured following intravenous administration of Ketogin 2 ml, containing ketobemido... |
|
|
The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene.
Pharmacol. Toxicol. 79(2) , 103-4, (1996)
|
|
|
Ketobemidone plus (RS)-3-dimethylamino-1,1-diphenylbut-1-ene (A29) is more potent at NMDA receptors than ketobemidone alone: evidence for A29 as a non-competitive NMDA receptor antagonist.
Pharmacol. Toxicol. 82(3) , 157-60, (1998) The opioid, ketobemidone, has previously been shown to be a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist. In Denmark, ketobemidone is available in a formulation which contains ketobemidone and a spasmolytic compound, (RS)-3-dimethylamino-1,... |
|
|
Analgesic effect and bioavailability of oral ketogan given as tablets or mixture to patients with chronic pain of malignant origin.
Acta Oncol. 27(5) , 583-9, (1988) Thirteen cancer patients with moderate to severe chronic pain of malignant origin on treatment with Ketogan tablets were included in an open non-randomized cross-over study comparing the analgesic effect, side effects and serum concentrations of Ketogan table... |
|
|
Premedication for day-case surgery: double-blind comparison of ketobemidone + dimethylaminodiphenylbuten (A-29) and morphine + scopolamine.
Acta Anaesthesiol. Scand. 30(7) , 502-6, (1986) A double-blind comparison of the effect of Ketogan (ketobemidone and A-29, an anticholinergic and spasmolytic agent) and morphine + scopolamine as premedication was performed in 113 women admitted for abortion and in 114 women admitted for gynaecological dila... |
|
|
Histamine release from human basophils and isolated rat mast cells induced by ketobemidone, pethidine and the spasmolytic A29.
Acta Pharmacol. Toxicol. (Copenh.) 50(1) , 78-80, (1982)
|